Loading...
Powered By
13 items
2025-06-24
Zeria Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 05, 2025
2025-05-30
Zeria Pharmaceutical Co., Ltd. expected to report Q1 2026 results on August 1, 2025. This event was calculated by S&P Global (Created on July 1, 2025).
2025-05-13
Zeria Pharmaceutical Co., Ltd. provided earnings guidance for the six months and full year period of the fiscal year ending March 31, 2026. For the six months, the company expects net sales of JPY 43, 000 million, operating profit of JPY 5,000 million, Profit attributable to owners of parent of JPY 4,000 million and Basic earnings per share of JPY 90.75 per share. For the full year, the company expects net sales of JPY 90,000 million, operating profit of JPY 12,000 million, Profit attributable to owners of parent of JPY 9,500 million and Basic earnings per share of JPY 215.52 per share.
2025-05-13
Zeria Pharmaceutical Co., Ltd. provided dividend guidance for the year-end period of the fiscal year ending March 31, 2026. For the period, the company expects to pay dividend of JPY 24 per share against JPY 24 per share paid a year ago.
2025-05-08
Zeria Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025.
2025-05-08
Zeria Pharmaceutical Co., Ltd., Board Meeting, May 08, 2025. Agenda: To consider Concerning Dividends from Surplus (Increase).
2025-03-25
Zeria Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 08, 2025
2025-02-21
Zeria Pharmaceutical Co., Ltd. provided dividend guidance of JPY 23.00 per share for the year ending March 31, 2025 against JPY 22.00 per share paid a year ago.
2025-02-10
Zeria Pharmaceutical Co., Ltd. revised consolidated financial guidance for Fiscal Year Ending March 31, 2025. For the period, the company expects Net sales of JPY 86,500 million against the previous guidance of JPY 86,000 million, Operating profit of JPY 12,000 million against the previous guidance of JPY 11,000 million, Profit attributable to owners of parent of JPY 9,000 million against the previous guidance of JPY 8,500 million and Basic earnings per share of JPY 204.18 against the previous guidance of JPY 192.83.
2025-01-03
Zeria Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 05, 2025
2024-11-11
Zeria Pharmaceutical Co., Ltd. announced second quarter-end dividend for the fiscal year ending March 31, 2025. For the period, the company announced to pay a dividend of JPY 23.00 per share against JPY 22.00 per share paid a year ago. Scheduled date to commence dividend payments: December 2, 2024.
2024-11-07
Zeria Pharmaceutical Co., Ltd., ¥ 23.0, Cash Dividend, Mar-28-2025
2024-09-20
Zeria Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 06, 2024
2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 | 2024Q1 | 2023Q4 | 2023Q3 | |
|---|---|---|---|---|---|---|---|---|
Total Revenues | 85,345 | 87,311 | 82,579 | 81,469 | 78,876 | 75,725 | 74,573 | 71,349 |
Pretax Income Excl.Unusual Items | 9,042 | 12,840 | 9,729 | 10,966 | 10,616 | 8,512 | 10,066 | 7,891 |
Total Assets | 151,219 | 159,171 | 156,580 | 158,339 | 152,115 | 150,533 | 153,067 | 148,158 |
Total Liabilities | 63,598 | 69,375 | 71,342 | 69,773 | 69,939 | 70,705 | 74,330 | 72,197 |
Cash & Cash Equivalents | 19,978 | 23,592 | 24,517 | 24,360 | 19,897 | 20,323 | 19,534 | 18,468 |
Total Common Equity | 87,436 | 89,539 | 85,059 | 88,267 | 81,931 | 79,622 | 78,469 | 75,702 |
Book Value Per Share (BVPS) | 1,983.6 | 2,031.31 | 1,929.67 | 2,002.45 | 1,858.7 | 1,806.31 | 1,780.15 | 1,717.37 |
Net Change in Cash | 4,863 | 3,826 | 2,510 | 3,173 | ||||
Capital Expenditure | -1,429 | -2,238 | -2,900 | -2,887 |
As of August 05, 2025, Zeria Pharmaceutical published financial results for the second quarter of 2025, with revenues of 19.49B yen and net income of 1.09B yen, reflecting a 9.2% decline in revenue, along with a sharp drop of approximately 74.1% in EPS compared with the same quarter last year. A negative aspect is that this latest revenue figure breaks a series of 2th consecutive quarters in which the company exhibited growth compared to the corresponding quarter of the previous year, raising concerns about the company's ability to sustain its growth trajectory.
Moreover, the EBITDA margin decreased significantly from 27.2% to 17.5% in the comparable quarter previous year. A decline in operating profitability can signify a problem with sales or a rise in operating expenses, which could be detrimental to the stock's performance in the future. and it trades at 13.4x times current year's earnings, which is higher than the sector average (P/E 9.6x).